Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1927 - SPAZO2 (SOGUG): Validation of the International Metastatic Database Consortium (IMDC) prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib (1stPz) in metastatic renal cell carcinoma (mRC).


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Renal Cell Cancer


Begoña Pérez-Valderrama


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


B. Pérez-Valderrama1, J. Arranz Arija2, I. Chirivella González3, U. Anido Herranz4, J.M. Jurado García5, C. Suarez Rodriguez6, I. García Carbonero7, G. de Velasco8, R. García Domínguez9, R.D. García Marrero10, M.A. Gonzalez Del Alba Baamonde11, C. Molins Palau12, M.E. Lazaro13, J. Munoz-Langa14, E. Martinez Ortega15, A. Hernández Jorge16, M. Campayo Guillaumes17, M. Sereno Moyano18, R. Luque Caro19, Á. Rodríguez Sánchez20

Author affiliations

  • 1 Medical Oncology, HH Virgen del Rocío, 41013 - Sevilla/ES
  • 2 Medical Oncology, Hospital General Universitario Gregorio Marañon, 28007 - Madrid/ES
  • 3 Medical Oncology, Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 4 Medical Oncology, Hospital Clinico Universitario de Santiago de Compostela, 15706 - Santiago de Compostela/ES
  • 5 Medical Oncology, Hospital Clinico San Cecilio, 18150 - Granada/ES
  • 6 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 7 Medical Oncology, Hospital Virgen de la Salud, 49004 - Toledo/ES
  • 8 Medical Oncology, Hospital 12 de Octubre, 28041 - Madrid/ES
  • 9 Medical Oncology, Hospital Universitario de Salamanca, 37007 - Salamanca/ES
  • 10 Medical Oncology, Hospital Universitario de Canarias, 38320 - Santa Cruz de Tenerife/ES
  • 11 Medical Oncology, Hospital Universitario Son Espases, 7010 - Palma de Mallorca/ES
  • 12 Medical Oncology, Hospital Universitario Dr Peset, 46017 - Valencia/ES
  • 13 Medical Oncology, Hospital Universitario Alvaro Cunqueiro, 36312 - Vigo/ES
  • 14 Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 15 Medical Oncology, Complejo Hospitalario de Jaen Universidad de Jaen, 23007 - Jaen/ES
  • 16 Medical Oncology, Onkologikoa, 20014 - Donostia/ES
  • 17 Medical Oncology, H. Mutua de Terrassa, 08221 - Terrassa/ES
  • 18 Medical Oncology, Hospital Infanta Sofia, 28702 - Madrid/ES
  • 19 Medical Oncology, HOSPITAL VIRGEN DE LAS NIEVES, Granada/ES
  • 20 Medical Oncology, Complejo Asistencial Universiario de Leon, 24071 - Leon/ES


Abstract 1927


Only 2% of pt included in the IMDC prognostic model for 2nd-line targeted agents in mRC had received 1stPz (Ko, Lancet Oncol 2015). We aimed to validate the IMDC model for this population of patients receiving 1stPz.


SPAZO2 (NCT03091465) was a retrospective real-world study to analyze the effectiveness of 1stPz and subsequent therapies in mRC in several settings in every day practice. Data from 530 pt treated with frontline pazopanib outside CT in 50 centers in Spain were collected by investigators, but monitored and entered in a database by an external CRO.


A total of 285 pt received antiVEGF or mTOR inhibitor as 2nd line (37.6% everolimus, 2.5% temsirolimus, 36% axitinib, 9.9% sunitinib, 8.3% sorafenib, 2.9% cabozantinib, 2.1% pazopanib, 0.4% beva-Inf, 0.4% savolitinib), 242 after true progression and 43 due to other causes after 1stPz. Unlike in IMDC, no pt had received 1st-line immunotherapy. Mean age was 66 y, 67.7% were male, 74.4% nephrectomized, and 12.3% pure nonclear-cell. Metastatic sites were: lung 74%, lymph nodes 55%, bone 36%, soft tissue/skin 27%, liver 24.8%, CNS 7%, adrenal gland 5%, pleura/peritoneum 6%, pancreas 5%, kidney 3% and other organs 2%. Classification of pt into the IMDC risk groups were: favorable (FR, 14.4%), intermediate (IR: 64.2%), or poor (PR: 21.4%). Median follow-up since 2nd-line was 29 mo; 67% of pt has progressed, 64% had received or subsequent lines, and 73% had died. Response, PFS and OS (and 95%CI) since 2nd-line are showed in the table. Differences in PFS and OS were statistically significant among groups (FR vs IR and FR vs PR). The C-Index was 0.635 (95%CI: 0.627 – 0.642). We also provide an estimation of outcomes according to if pt received 2ndline after “true progression” or due to any cause.Table:


ORR14.6%22.5%15.8%5.5%Not reposted
Median PFS (1)*5.1 (4-6)11.5 (5-18)5 (4-6)3 (2-4)3.9Not reported
Median PFS (2)*4.7 (4-5)9.7 (4-15)4.8 (4-6)3 (2-4)
Median OS (1)*11.3 (9-13)24.4 (18-30)12.7 (10-15)6.5 (5-8)12.5 (11-14)35.3 (28-48)16.6 (15-18)5.4 (5-7)
Median OS (2)*11.1 (9-13)19.8 (12-27

Months; 1: 2nd-line due to any cause (N = 285); 2: 2nd-line due to progression to Pz (N = 242).


Our results validate the use of the IMDC prognostic classification as a discrimination tool, for predicting prognosis in pt receiving 2nd-line targeted therapies after pazopanib in mRC. Pt who received 2nd-line after true progression had a poorer prognostic than the predicted by the IMDC.

Clinical trial identification


Legal entity responsible for the study





B. Pérez-Valderrama: Consulting/Advisory role for Astellas Pharma, Novartis, Pfizer, Pierre Fabre, Bayer, Sanofi, Bristol-Myers Squib and Roche. J. Arranz Arija: AdBo from Novartis and Pfizer. G. de Velasco: Consulting and Advisory board for Pfizer, Novartis, Bayer, Roche. M.A. Gonzalez Del Alba Baamonde: Advisory boards for Novartis, Pfizer, Bristol-Myers Squib, Ipsen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.